PHASEBIO PHARMACEUTICALS INC's ticker is PHAS and the CUSIP is 717224109. A total of 53 filers reported holding PHASEBIO PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $35,000 | -5.4% | 10,147 | -8.4% | 0.00% | – |
| Q4 2020 | $37,000 | +32.1% | 11,080 | +38.3% | 0.00% | – |
| Q3 2020 | $28,000 | -17.6% | 8,013 | +10.0% | 0.00% | – |
| Q2 2020 | $34,000 | +126.7% | 7,283 | +55.7% | 0.00% | – |
| Q1 2020 | $15,000 | -48.3% | 4,678 | -5.6% | 0.00% | – |
| Q4 2019 | $29,000 | -67.4% | 4,954 | -77.2% | 0.00% | – |
| Q3 2019 | $89,000 | -37.8% | 21,769 | +96.7% | 0.00% | – |
| Q2 2019 | $143,000 | +2283.3% | 11,069 | +418.2% | 0.00% | – |
| Q4 2018 | $6,000 | – | 2,136 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 1,607,044 | $4,194,000 | 0.48% |
| NEA Management Company, LLC | 6,643,704 | $17,340,000 | 0.35% |
| Platform Technology Partners | 251,723 | $657,000 | 0.29% |
| DAFNA Capital Management LLC | 378,611 | $988,000 | 0.25% |
| Avidity Partners Management LP | 4,405,000 | $11,497,000 | 0.24% |
| Endurant Capital Management LP | 360,078 | $940,000 | 0.23% |
| Rock Springs Capital Management LP | 2,581,299 | $6,737,000 | 0.16% |
| RA Capital Management | 2,850,000 | $7,439,000 | 0.13% |
| New Legacy Group, LLC | 240,575 | $628,000 | 0.12% |
| XTX Topco Ltd | 15,574 | $41,000 | 0.02% |